Puzzling Over the Hurt Down-Under
Serious Mental Illness and Contraception
New 13-Cycle Vaginal Contraceptive System
The Future of Family Planning in Post-COVID America
New ASCCP Guidelines: Implications for FP
On the alert: mood disorders during 2020 stressors
Challenges old and new during the pandemic
Reproductive health in the time of Covid-19
Missed Pills: The Problem That Hasn’t Gone Away
Find the “yes! . . . and” rather than “no” or “but”
Digital Family Planning: the Future is Now
Irregular Bleeding Due to Contraceptives
Ouch! Best approaches to menstrual pain
Contraceptive efficacy: understanding how user and method characteristics play their part
Strategizing treatment for chronic heavy menstrual bleeding
Untangling the literature on obesity and contraception
High tech apps for no-tech FABM
Menstrual exacerbation of other medical conditions
From Princeton University: Thomas James Trussell (1949-2018)
The Short and Long of IUD Use Duration
Selecting a Method When Guidance Isn’t Clear-cut
Healthcare in the Time of Digital Expansion
The Scoop on Two New FDA-Approved Contraceptive Methods
Pregnancy of unknown location—meeting the challenge
Big “yes” (with caveats) to CHCs during perimenopause
The role of IUDs (LNG IUDs, too!) in emergency contraception
Combined pills’ effect on mood disorders
Abortion in the U.S.: safe, declining, and under threat
Hope for ovarian cancer screening test
Breast cancer still a small risk with some hormonal contraceptives
Record rate of HPV-related throat cancer
Viruses in semen potentially transmissible
Don’t Abstain from Your Role in Abstinence
Teens births declining but geographic ‘hotspots’ defy trend
Online Medical Abortion Service Effective and Safe
Do Women Really Need to Wait That Long?
Reassuring news on depression and OC use
PMDD: Genetic clues may lead to improved treatment
Breast cancer risk when there is a family history
Body weight link to breast and endometrial cancers (and 11 others)
Family Planning in 2017 and Beyond
Make Me Cry: Depression Link (Again)?
Managing implant users’ bleeding and spotting
Zika: Updated guidance for providers
Pharmacist-prescribed contraceptives
Hot off the press! 2016 MEC and SPR
Zika virus fears prompt increased request for abortion in nations outlawing abortions
Opioid use epidemic among reproductive-age women
Good news on the family planning home front!
War Against Planned Parenthood Hurts Women
Win-win for both treatment and prevention
Menopause, mood, mental acuity, and hormone therapy
Emergency contraception for teens
Postpartum Contraception: Now, Not Later
Are we practicing what we preach?
Be alert to VTE in hormonal contraceptive users
LARC among teens increased 15-fold, but not enough
Brain cancer and hormonal contraception
Free tools: Easy access to the US Medical Eligibility Criteria for Contraceptive Use
Alcohol consumption when pregnancy is unwanted or unintended
Latest Data on Contraceptive Use in the United States
LateBreaker sampler from Contraceptive Technology conference
Emergency Contraceptive Pill Efficacy and BMI/Body Weight
Handout on Unintended Pregnancy and Contraceptive Choice
Ask About Withdrawal (Really!)
Rules to Practice By: Safety First and Cleanliness is Close to. . .
What’s Vanity Fair Got Against the NuvaRing?
Promising New Treatment for Hepatitis C
Numbers matter, so make them simple for patients
The Recession’s Effect on Unintended Pregnancies
Lessons Learned from the Contraceptive CHOICE Project: The Hull LARC Initiative
Applying the “New” Cervical Cytology Guidelines in Your Practice
Acute Excessive Uterine Bleeding: New Management Strategies
Medical indications for IUD use in teens

In September, a group of Danish investigators published in the JAMA Psychiatry an article entitled “Association of hormonal contraception with depression.”1 The authors concluded that “use of hormonal contraception, especially among adolescents, was associated with subsequent use of antidepressants and a first diagnosis of depression, suggesting depression as a potential adverse effect of hormonal contraceptive use.” The story was immediately picked up by most news outlets and spread virally. This enthusiasm occurred in spite of the fact that many earlier studies had found no association or even a reduced risk of depression symptoms.2 Some patients have started to ask again about this issue, and many more may be troubled by this new risk to their health.
So, what should we tell the patients?
The study included records of 1,061,997 women, with over 24 million person-years of use of a wide variety of hormonal methods with different progestogens, so it sounds very impressive. However, these numbers were generated from national registries (National Prescription Register and the Psychiatric Central Register) in Denmark. From these registries and “statistics Denmark,” the investigators were able to control for age, education level, diagnosis of PCOS and endometriosis. In addition, they got information about BMI and smoking for women (from the National Birth registry) at the time of their last pregnancy (please note that few of the teens would have had information available for BMI or smoking). Also, education levels of teens may be less relevant than for older women. A 16-year old woman is most likely to have no more than a high school education.
The authors tried to exclude women who had previously been diagnosed with any psychiatric condition by excluding women who had used antidepressant drugs or had depression diagnosis at any time for at least five years before study entry.
What were the results?
The incidence rate of first use of antidepressants among…
Hormonal contraceptive users: 2.2/100 person-years
Non-users* of hormonal contraceptives: 1.71/100 person-years
* Non-users = never or former hormonal users (> 6 months). These women may not be sexually active.
Detailed analyses were done by type of contraceptive method, type of progestin, amount of estrogen, and time between initiation of hormonal methods and treatment/diagnosis of depression.
How can you interpret these results?
Even though two things seem to be related, they must meet well-tested criteria before any claim can be made for causation. These are called the Bradford Hill criteria:
- Strength: The larger the association, the more likely it is causal. (The association between tobacco and lung cancer was 8.0; in this study the odds ratio was 2.3).
- Consistency: The authors themselves cited the conflicts seen in previous studies ranges from increased risk to reduced risk.
- Specificity: The authors were not able to control for many confounding factors.
- Temporality: The effect did occur after the start of pills, but longer exposure to pills actually resulted in lower risk of depression.
- Biologic gradient: (aka dose response). This was violated. The method with the lowest hormone levels (Mirena) had one of the highest relative risks.
- Plausibility: Several mechanisms were suggested, but these were weak.
- Coherence: Experiment, analogy. Not applicable.
Given that the strength of the effect was modest, except perhaps in teens, that there is no consistency among studies, that there was no dose effect, and that the risk decreased with prolonged exposure, it is hard to see why this paper was accepted by such a prestigious journal. Probably because it carried bad news for the pill. I wish you all the best trying to explain all this to your patient. Maybe saying the risk increased in only one woman in 200 could help.1
REFERENCES
- Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of hormonal contraception with depression. JAMA Psychiatry. 2016;73(11):1154-1162.
- Keyes KM, Cheslack-Postava K, Westhoff C, Heim CM, Haloossim M, Walsh K, Koenen K. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol. 2013;178(9):1378-88.
Submitted by: Anita Nelson, MD, professor emeritus of obstetrics and gynecology at the David Geffen School of Medicine at the University of California-Los Angeles and clinical professor at the University of Southern California